4-[[6-[(2-cyclopentylacetyl)amino]-4-oxoquinolin-1-yl]methyl]-3-methoxy-N-(2-methylphenyl)sulfonylbenzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[[6-[(2-cyclopentylacetyl)amino]-4-oxoquinolin-1-yl]methyl]-3-methoxy-N-(2-methylphenyl)sulfonylbenzamide
• 化学式: C₃₂H₃₃N₃O₆S
• 分子量: 587.697
• InChiKey: XIOGIPOEBZZIMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  130
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-溴甲基-3-甲氧基苯甲酸甲酯 在 palladium on activated charcoal 4-二甲氨基吡啶 、 lithium hydroxide 、 ammonium formate 、 sodium hydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 78.5h， 生成 4-[[6-[(2-cyclopentylacetyl)amino]-4-oxoquinolin-1-yl]methyl]-3-methoxy-N-(2-methylphenyl)sulfonylbenzamide
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists

  摘要：

  This paper describes the synthesis and pharmacological evaluation of three series of compounds 4a-b, 13a-k and 19, structurally related to the known potent cysLT(1) receptor antagonists RG-12553, ICI-204219 and ONO-1078, respectively. The common structural feature of these new series is the presence of a 4-quinolone nucleus acting as a template for substitution of the aromatic nucleus present in the prototype antagonists. We describe the evolution of these series leading to antagonists with potency at nanomolar concentrations in vitro.

  DOI：

  10.1016/s0223-5234(97)83282-5

文献信息

• Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists
  作者：R Griera、M Armengol、A Reyes、M Alvarez、A Palomer、F Cabré、J Pascual、M.L. Garcia、D Mauleón

  DOI：10.1016/s0223-5234(97)83282-5

  日期：1997.7

  This paper describes the synthesis and pharmacological evaluation of three series of compounds 4a-b, 13a-k and 19, structurally related to the known potent cysLT(1) receptor antagonists RG-12553, ICI-204219 and ONO-1078, respectively. The common structural feature of these new series is the presence of a 4-quinolone nucleus acting as a template for substitution of the aromatic nucleus present in the prototype antagonists. We describe the evolution of these series leading to antagonists with potency at nanomolar concentrations in vitro.